Skip to main
OM
OM logo

Outset Medical (OM) Stock Forecast & Price Target

Outset Medical (OM) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 30%
Hold 20%
Sell 10%
Strong Sell 0%

Bulls say

Outset Medical's recurring revenue model, bolstered by treatment orders and a growing console base, positions the company for sustained success, particularly as it aligns its sales execution with enterprise needs. The company is on track to expand gross margins through a mix of higher-margin recurring sales, cost reductions from production shifts, and increasing adoption of its Tablo machine, which provides a competitive edge in the dialysis market. Sales are projected to grow from $115 million in 2022 to $127 million by 2025, and reach approximately $191 million by 2028, reflecting a solid long-term growth trajectory driven by ongoing adoption.

Bears say

Outset Medical's Q2 2024 results fell short of consensus expectations, leading to a significant reduction in 2024 revenue guidance from $145-153 million to approximately $110 million, equating to a notable year-over-year decline of 15.6%. The company reported a year-over-year revenue drop of 24% and a slight sequential decline of 2.8%, signaling potential challenges in maintaining growth. Additionally, factors such as slower-than-expected adoption of the Tablo system in acute care settings and increased competition present further risks to revenue growth and overall market position.

Outset Medical (OM) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outset Medical (OM) Forecast

Analysts have given Outset Medical (OM) a Buy based on their latest research and market trends.

According to 10 analysts, Outset Medical (OM) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outset Medical (OM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.